Health Canada granted marketing authorization with conditions (Notice of Compliance with Conditions (NOC/c)) for tofersen on 03rd Mar, 2025, for the treatment of adults with ALS associated with a mutation in the SOD1 gene [145]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.